CINGW Cingulate Inc. - Warrants
0.0060USD-10.45%Mkt Cap: —P/E: —8d ago
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United Sta…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit-8.52M USD
Net Income (TTM)-22.45M USD
Revenue/Share—
Last Price0.0060 USD
Fiscal Year End—
MR Quarter—
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.00
EPS (TTM)-1.73
EPS (Forward)—
52W Range
0.00266% of range0.0601
52W High0.0601 USD
52W Low0.0026 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-894.81%
ROA-148.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.25M USD
CapEx (TTM)162.14K USD
FCF Margin—
FCF Yield—
Net Debt-22.11M USD
Net Debt/EBITDA0.90
Balance Sheet
Debt/Equity3.50
Current Ratio3.50
Quick Ratio3.30
Book Value/Sh1.69 USD
Cash/Share1.95 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float14.20M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta-0.88
S&P 52W Chg15.78%
Avg Vol (30d)24.70K
Avg Vol (10d)—
Technical Indicators
RSI (14)42.6
MACD-0.0032
MACD Signal-0.0036
MACD Hist.+0.0004
BB Upper0.0123 USD
BB Middle0.0084 USD
BB Lower0.0044 USD
BB Width94.73%
ATR (14)0.0040 USD
Vol Ratio (20d)0.01x